Project Grant R43HL184836
Award Date 9/1/26
Completion Date 4/30/28
Dollars Obligated $374K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92617, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Environment & Health Group Inc. $314,321 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop HeartSense.AI, a generative AI-driven mobile health solution for hypertension self-management in lower-income adults. The application describes an mHealth platform that integrates a generative AI model with home-based blood pressure monitoring, digital pill reminders, and non-physician-led telehealth to...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Autonomous Healthcare Inc. $305,999 on September 1, 2026, under the Small Business Innovation Research (SBIR) program to conduct a Phase I feasibility study of E-Fusion, a bedside clinical decision support system designed to assist anesthesiologists, anesthetists, and critical care nurses with vasopressor titration and blood pressure management during surgery and in the intensive care unit. The system monitors mean arterial pressure (MAP) and...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $803,081 on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an artificial intelligence system for improved diagnosis, prognosis, and management of acute pulmonary embolism. The recipient will build a vision foundation model integrating high-dimensional computed tomography pulmonary angiography (CTPA) imaging features,...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded Brigham & Women's Hospital Inc. $894,718 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on optimal prescribing of oral anticoagulants in patients with venous thromboembolism and cirrhosis. The research addresses a critical evidence gap in anticoagulation therapy for cirrhosis patients...
- The National Heart, Lung, and Blood Institute awarded Icardio.ai Corporation $290,142 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, for an artificial intelligence-enabled diagnostic support system for echocardiography. Performance of the award concludes on August 31, 2027, at the recipient's location in Century City, California. The project addresses the shortage of trained echocardiographers and the infrastructure constraints that limit adoption of...
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $858,456 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL184047) to develop and test an interoperable shared decision-making tool integrated into electronic health records for stroke prevention in atrial fibrillation patients. The project, titled DECIDE-AF, addresses suboptimal anticoagulation initiation and persistence among AF...
- The National Heart, Lung, and Blood Institute awarded Lynntech Inc. $319,607 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and demonstrate the feasibility of BreathWise, an AI-driven early-warning system for COPD exacerbations. BreathWise integrates multimodal physiological, behavioral, and environmental sensing with machine learning-based predictive analytics to identify COPD patients at imminent risk of exacerbation. The system continuously...